What Eyestem does
Founded in 2016, Eyestem operates in Health Tech industry. Initially aimed at combating conditions like age-related macular degeneration, the company has evolved to include diverse cell therapy solutions tailored for retinal and lung diseases. Eyestem marked a significant development by advancing towards clinical trials for its flagship product, EyeCyte-RPE, signaling a potential breakthrough in treating vision impairment. The company has extended its research capabilities by incorporating cutting-edge stem cell technology to enhance treatment efficacy. Competing with companies such as 4baseCare and NKure Therapeutics.
Who runs it
Funding and finances
Why this matters to you: funding stage is a rough proxy for how long the runway is and how much structure to expect. It is not a promise, and a profitable bootstrapped company can be the safer bet.
Check the company’s own careers page — linked at the top — before a job board. A role appears there first, sometimes weeks before it is syndicated anywhere else.
Questions and experiences
Nobody has asked anything about Eyestem yet. If you have interviewed here, what you know is worth more to the next person than anything on the rest of this page.
Company facts compiled from public sources and last refreshed 9 September 2026. Details change; treat the company’s own site as the authority.